Metformin and Dolutegravir/Lamivudine Interaction

Understanding the Metformin and Dolutegravir/Lamivudine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Metformin belongs to the Biguanide class and Dolutegravir/Lamivudine belongs to the Integrase Inhibitor / NRTI Combination class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dolutegravir blocks the proteins that help your kidneys remove metformin, which can lead to higher levels of metformin in your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Metformin has 27 total documented interactions on file in this dataset, and Dolutegravir/Lamivudine has 9. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Talk to your doctor about the risks of this combination, as they may need to adjust your metformin treatment. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Metformin or Dolutegravir/Lamivudine based on a web page, speak with your prescriber or pharmacist before making any change.